Research interest

We have a major focus on bowel cancer genomics, the application of high-throughput molecular profiling technologies to identify principal cancer genes and biomarkers of cancer risk and prognosis. We are conducting next-generation sequencing and microarray studies involving Australian and international patient cohorts to define molecular signatures associated with tumour characteristics and outcome.

Patient-focused investigations are being complemented with functional studies on cancer cell lines to distinguish driver from passenger mutations and to gain insights into molecular pathways of carcinogenesis. Molecularly-annotated cancer cell lines are further being used to explore the efficacy of novel drug therapies, both as single-agents and in combination with standard therapies.